FindTrial
Sign In

X-82

DRUG3 trials

Sponsors

Tyrogenex, Washington University School of Medicine

Conditions

AMDAdenocarcinomaAdvanced Solid TumorsAge-Related Macular Degeneration (AMD)Exudative Age-related Macular DegenerationEye DiseasesMacular DegenerationMacular Degeneration, Age-related, 10

Phase 1

Safety Study of X-82 in Patients With Advanced Solid Tumors
CompletedNCT01296581
TyrogenexAdvanced Solid Tumors
Start: 2011-02-28End: 2017-01-31Updated: 2022-02-28
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
TerminatedNCT01784861
Washington University School of MedicineAdenocarcinoma, Pancreatic Neoplasms
Start: 2013-05-03End: 2020-08-19Updated: 2021-07-08

Phase 2

X-82 to Treat Age-related Macular Degeneration
TerminatedNCT02348359
TyrogenexAge-Related Macular Degeneration (AMD), AMD, Exudative Age-related Macular Degeneration +5
Start: 2015-03-16End: 2018-01-12Updated: 2022-02-11

Related Papers

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
2021-03-1820 citations
Phase I study of X-82, an oral dual anti-VEGFR/PDGFR tyrosine kinase inhibitor, with everolimus in solid tumors.
Journal of Clinical Oncology2016-05-203 citations